Publications

BibTex format

@article{Muñoz-Martínez:2021:10.1016/j.jhepr.2021.100260,
author = {Muñoz-Martínez, S and Sapena, V and Forner, A and Nault, J-C and Sapisochin, G and Rimassa, L and Sangro, B and Bruix, J and Sanduzzi-Zamparelli, M and Hoówko, W and El, Kassas M and Mocan, T and Bouattour, M and Merle, P and Hoogwater, FJH and Alqahtani, SA and Reeves, HL and Pinato, DJ and Giorgakis, E and Meyer, T and Villadsen, GE and Wege, H and Salati, M and Mínguez, B and Di, Costanzo GG and Roderburg, C and Tacke, F and Varela, M and Galle, PR and Alvares-da-Silva, MR and Trojan, J and Bridgewater, J and Cabibbo, G and Toso, C and Lachenmayer, A and Casadei-Gardini, A and Toyoda, H and Lüdde, T and Villani, R and Matilla, Peña AM and Guedes, Leal CR and Ronzoni, M and Delgado, M and Perelló, C and Pascual, S and Lledó, JL and Argemi, J and Basu, B and da, Fonseca L and Acevedo, J and Siebenhüner, AR and Braconi, C and Meyers, BM and Granito, A and Sala, M and Rodríguez, Lope C and Blaise, L and Romero-Gómez, M and Piñero, F and Gomez, D and Mello, V and Pinheiro, Alves RC and F},
doi = {10.1016/j.jhepr.2021.100260},
journal = {JHEP Reports},
title = {Assessing the impact of COVID-19 on liver cancer management (CERO-19)},
url = {http://dx.doi.org/10.1016/j.jhepr.2021.100260},
volume = {3},
year = {2021}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: The coronavirus 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). This project has evaluated if the schedule of LC screening or procedures has been interrupted /delayed because of the COVID-19 pandemic. MATERIAL AND METHODS: An international survey evaluated the impact of COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave. RESULTS: Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia and Africa (73.7%, 17.1%, 5.3%, 2.6% and 1.3% per continent, respectively). Eighty-seven per cent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening program, 50% cancelled curative and/or palliative treatments for LC, and 44.0% cancelled the liver transplantation program. Forty-five out 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service prior to COVID-19 pandemic (n=19/37). CONCLUSION: The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with LC. Modifications in screening, diagnostic and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision making.
AU  - Muñoz-Martínez,S
AU  - Sapena,V
AU  - Forner,A
AU  - Nault,J-C
AU  - Sapisochin,G
AU  - Rimassa,L
AU  - Sangro,B
AU  - Bruix,J
AU  - Sanduzzi-Zamparelli,M
AU  - Hoówko,W
AU  - El,Kassas M
AU  - Mocan,T
AU  - Bouattour,M
AU  - Merle,P
AU  - Hoogwater,FJH
AU  - Alqahtani,SA
AU  - Reeves,HL
AU  - Pinato,DJ
AU  - Giorgakis,E
AU  - Meyer,T
AU  - Villadsen,GE
AU  - Wege,H
AU  - Salati,M
AU  - Mínguez,B
AU  - Di,Costanzo GG
AU  - Roderburg,C
AU  - Tacke,F
AU  - Varela,M
AU  - Galle,PR
AU  - Alvares-da-Silva,MR
AU  - Trojan,J
AU  - Bridgewater,J
AU  - Cabibbo,G
AU  - Toso,C
AU  - Lachenmayer,A
AU  - Casadei-Gardini,A
AU  - Toyoda,H
AU  - Lüdde,T
AU  - Villani,R
AU  - Matilla,Peña AM
AU  - Guedes,Leal CR
AU  - Ronzoni,M
AU  - Delgado,M
AU  - Perelló,C
AU  - Pascual,S
AU  - Lledó,JL
AU  - Argemi,J
AU  - Basu,B
AU  - da,Fonseca L
AU  - Acevedo,J
AU  - Siebenhüner,AR
AU  - Braconi,C
AU  - Meyers,BM
AU  - Granito,A
AU  - Sala,M
AU  - Rodríguez,Lope C
AU  - Blaise,L
AU  - Romero-Gómez,M
AU  - Piñero,F
AU  - Gomez,D
AU  - Mello,V
AU  - Pinheiro,Alves RC
AU  - França,A
AU  - Branco,F
AU  - Brandi,G
AU  - Pereira,G
AU  - Coll,S
AU  - Guarino,M
AU  - Benítez,C
AU  - Anders,MM
AU  - Bandi,JC
AU  - Vergara,M
AU  - Calvo,M
AU  - Peck-Radosavljevic,M
AU  - García-Juárez,I
AU  - Cardinale,V
AU  - Lozano,M
AU  - Gambato,M
AU  - Okolicsanyi,S
AU  - Arraez,DM
AU  - Elvevi,A
AU  - Muñoz,AE
AU  - Lué,A
AU  - Iavarone,M
AU  - Reig,M
DO  - 10.1016/j.jhepr.2021.100260
PY  - 2021///
SN  - 2589-5559
TI  - Assessing the impact of COVID-19 on liver cancer management (CERO-19)
T2  - JHEP Reports
UR  - http://dx.doi.org/10.1016/j.jhepr.2021.100260
UR  - https://www.ncbi.nlm.nih.gov/pubmed/33644725
UR  - https://www.sciencedirect.com/science/article/pii/S2589555921000367?via%3Dihub
UR  - http://hdl.handle.net/10044/1/86631
VL  - 3
ER  -

Download

Dr. David James PINATO

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)